DNA
Ginkgo Bioworks·NYSE
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 4
Ample Liquidity
High Gross Profit Margin
Significant Revenue Decline
Price Hits New Low
Price Hits 52-week Low
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About DNA
Ginkgo Bioworks Holdings, Inc.
A leading platform for cell programming and biosecurity
Biological Technology
10/22/2020
09/17/2021
New York Stock Exchange
834
12-31
Common stock
27 Drydock Avenue, 8th Floor, Boston, MA 02210
--
Ginkgo Bioworks Holdings, Inc., was incorporated and registered in Delaware on October 22, 2020. Ginkgo Bioworks is a leading platform for cellular programming, providing flexible end-to-end services that solve challenges for organizations in diverse markets such as food and agriculture, pharmaceuticals, industrial and specialty chemicals. Concentric by Ginkgo, Ginkgo's biosafety and public health division, is building a global biosafety infrastructure to empower governments, communities and public health leaders to prevent, detect and respond to a wide variety of biological threats.
Earnings Call
Q1/2025
Estimate EPS--
Actual EPS-1.68
Estimate Revenue38.70M
Actual Revenue48.32M
Ginkgo Bioworks Q1 2025: Key Contradictions in Revenue Expectations, Market Pressures, and Government Contracts
May 07,2025 07:24
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS--
Actual EPS-1.1
Estimate Revenue41.60M
Actual Revenue49.60M
Ginkgo Bioworks Q2 2025: Unpacking Contradictions in Acquisition Strategy, Revenue Expectations, and Growth Focus
Aug 08,2025 03:22
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
DNA has released its 2025 Q3 earnings. EPS was reported at -1.45, versus the expected -1.24, missing expectations. The chart below visualizes how DNA has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
DNA has released its 2025 Q3 earnings report, with revenue of 38.84M, reflecting a YoY change of -56.39%, and net profit of -80.75M, showing a YoY change of -43.18%. The Sankey diagram below clearly presents DNA's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
